Recombinant PDCD1 (Nivolumab Biosimilar) 抗体
This anti-PDCD1 (Nivolumab Biosimilar) antibody is a Humanized 单克隆 antibody detecting PDCD1 (Nivolumab Biosimilar) in FACS 和 in vivo. Suitable for 人.
Quick Overview for Recombinant PDCD1 (Nivolumab Biosimilar) 抗体 (ABIN7200667)
抗原
PDCD1 (Nivolumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This PDCD1 (Nivolumab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
克隆位点
5C4-B8
-
-
原理
- Nivolumab Biosimilar, Human PD-1 Monoclonal Antibody
-
特异性
- The in vivo grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.
-
产品特性
- What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1). Nivolumab blocks PD-1 inhibitory signalling to T-cells. It has a long duration of action as it is administered every 2-4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity. The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
过滤
- 0.2 μm filtered
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody nivolumab biosimilar was produced in the nivolumab biosimilar CHO stable cell line.
-
亚型
- IgG4
-
-
-
-
应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
-
储存液
- Without preservative
-
储存条件
- 4°C,-20 °C
-
储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
-
有效期
- 12 months
-
-
- PDCD1 (Nivolumab Biosimilar)
-
别名
- Nivolumab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
